Is there a role for TNF-α antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique

Clinical and Experimental Rheumatology

Volumn 29, Issue 2 SUPPL. 65, 2011, Pages

  Distler, J H W ^a   Jordan, S ^b   Airo P ^c   Alegre Sancho, J J ^d   Allanore, Y ^e   Balbir Gurman, A ^f   Caporali, R ^g   Caramaschi, P ^h   Carreira, P E ⁱ   Chizzolini, C ^j   Cutolo, M ^k   Tuncay Duruoz M ^l   Farge Bancel, D ^m   Hesselstrand, R ⁿ   Iannone, F ^o   De Keyser, F ^p   Kucharz, E J ^q   Launay, D ^r   Garcia De La Pena Lefebvre P ^s   Lukacova, O ^t   Marasini, B ^u   Martinovic, D ^v   Marques Neto, J F ^w   Radic, M ^v   Rednic, S ^x   Riemekasten, G ^y   Rovensky, J ^t   Seidel, M F ^z   Senel, S ^aa   Smith, V ^p   Sunderkotter C ^ab   Ton, E ^ac   Van Laar, J M ^ad   Matucci Cerinic, M ^ae   Muller Ladner U ^af   Distler, Oliver ^b   more..

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Rheumatology and Clinical Immunology Unit   (Italy)

^d HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f B Shine Department of Rheumatology   (Israel)

^g UNIVERSITY OF PAVIA   (Italy)

^h Rheumatology Unit   (Italy)

ⁱ HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^j UNIVERSITY HOSPITAL   (Switzerland)

^k UNIVERSITY OF GENOA   (Italy)

^l CELAL BAYAR UNIVERSITY   (Turkey)

^m SAINT LOUIS HOSPITAL   (France)

ⁿ LUND UNIVERSITY HOSPITAL   (Sweden)

^o UNIVERSITY OF BARI   (Italy)

^p GHENT UNIVERSITY HOSPITAL   (Belgium)

^q MEDICAL UNIVERSITY OF SILESIA   (Poland)

^r UNIV LILLE   (France)

^s Hospital Universitario Madrid Norte Sanchinarro   (Spain)

^t National Institute for Rheumatic Diseases   (Slovakia)

^u UNIVERSITY OF MILAN   (Italy)

^v UNIVERSITY HOSPITAL SPLIT   (Croatia)

^w UNIVERSITY OF CAMPINAS   (Brazil)

^x IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^y CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^z UNIVERSITY HOSPITAL BONN   (Germany)

^aa CUMHURIYET UNIVERSITY   (Turkey)

^ab UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^ac UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^ad NEWCASTLE UNIVERSITY   (United Kingdom)

^ae UNIVERSITY OF FLORENCE   (Italy)

^af JUSTUS LIEBIG UNIVERSITY   (Germany)

more..

Author keywords

Fibrosis; Scleroderma; TNF

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA ANTAGONIST; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; ADALIMUMAB; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB;

ARTHRITIS; ARTICLE; CLINICAL ASSESSMENT TOOL; DELPHI STUDY; FIBROSIS; HUMAN; LUPUS VULGARIS; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME; TREATMENT PLANNING; CALCINOSIS; CONSENSUS DEVELOPMENT; DETERIORATION; DRUG DOSE REDUCTION; DYSPHAGIA; ENTHESOPATHY; FATIGUE; LUNG ALVEOLITIS; LUNG FIBROSIS; LUPUS LIKE SYNDROME; MORPHEA; MYOSITIS; OFF LABEL DRUG USE; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; TENDINITIS; TREATMENT INDICATION;

ANTI-INFLAMMATORY AGENTS; ARTHRITIS; CONSENSUS; DELPHI TECHNIQUE; DISEASE PROGRESSION; FIBROSIS; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; OFF-LABEL USE; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79960431442     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. KEYSER FD, MIELANTS H, VEYS EM: Current use of biologicals for the treatment of spondyloarthropathies. Expert Opin Pharmacother 2001;2:85-93.
2. OLSEN NJ, STEIN CM: New drugs for rheumatoid arthritis. N Engl J Med 2004; 350: 2167-79.
3. CHUA CC, CHUA BH: Tumor necrosis factor-alpha induces mRNA for collagenase and TIMP in human skin fibroblasts. Connect Tissue Res 1990; 25: 161-70.
4. MAUVIEL A, DAIREAUX M, REDINI F, GALERA P, LOYAU G, PUJOL JP: Tumor necrosis factor inhibits collagen and fibronectin synthesis in human dermal fibroblasts. FEBS Lett 1988; 236: 47-52.
5. LIU JY, BRASS DM, HOYLE GW, BRODY AR: TNF-alpha receptor knockout mice are protected from the fibroproliferative effects of inhaled asbestos fibers. Am J Pathol 1998; 153: 1839-47.
6. PIGUET PF, VESIN C: Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur Respir J 1994; 7: 515-8.
7. KHAN SB, COOK HT, BHANGAL G, SMITH J, TAM FW, PUSEY CD: Antibody blockade of TNF-alpha reduces inflammation and scarring in experimental crescentic glomerulonephritis. Kidney Int 2005; 67: 1812-20.
8. DISTLER JH, SCHETT G, GAY S, DISTLER O: The controversial role of tumor necrosis factor alpha in fibrotic diseases. Arthritis Rheum 2008; 58: 2228-35.
9. VARGA J, ABRAHAM D: Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 557-67.
10. GABRIELLI A, AVVEDIMENTO EV, KRIEG T: Scleroderma. N Engl J Med 2009; 360: 1989-2003.
11. BOSELLO S, DE SANTIS M, TOLUSSO B, ZOLI A, FERRACCIOLI G: Tumor necrosis factor-alpha inhibitor therapy in erosive polyarthritis secondary to systemic sclerosis. Ann Intern Med 2005; 143: 918-20.
12. ANTONIOU KM, MAMOULAKI M, MALAGARI K et al.: Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin Exp Rheumatol 2007; 25: 23-8.
13. BARGAGLI E, GALEAZZI M, BELLISAI F, VOLTERRANI L, ROTTOLI P: Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension. Respiration 2008; 75: 346-9.
14. DENTON CP, ENGELHART M, TVEDE N et al.: An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2009; 68: 1433-9.
15. ELLMAN MH, MACDONALD PA, KATZ RS: Open label use of etanercept in eight scleroderma patients. Ann Rheum Dis 2003; 62 (Suppl. I): 229.
16. LAM GK, HUMMERS LK, WOODS A, WIGLEY FM: Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease. J Rheumatol 2007 Jul; 34: 1636-7.
17. ALEXIS AF, STROBER BE: Off-label dermatologic uses of anti-TNF-α therapies. J Cutan Med Surg 2005; 9: 296-302.
18. AVOUAC J, WALKER U, TYNDALL A et al.: Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol 2010; 37: 1488-501.
19. KHANNA D, AGRAWAL H, CLEMENTS PJ: Infliximab may be effective in the treatment of steroid-resistant eosinophilic fasciitis: report of three cases. Rheumatology (Oxford). 2010; 49: 1184-8.
20. TZARIBACHEV N, HOLZER U, SCHEDEL J, MAIER V, KLEIN R, KUEMMERLE-DESCHNER J: Infliximab effective in steroid-dependent juvenile eosinophilic fasciitis. Rheumatology (Oxford). 2008; 47: 930-2.
21. ALLANORE Y, DEVOS-FRANCOIS G, CARAMELLA C, BOUMlER P, JOUNIEAUX V, KAHAN A: Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab. Ann Rheum Dis 2006; 65: 834-5.
22. MARIE I, LAHAXE L, LEVESQUE H, HELlOT P: Pulmonary actinomycosis in a patient with diffuse systemic sclerosis treated with infliximab. QJM 2008; 101: 419-21.
23. OSTOR AJ, CRISP AJ, SOMERVILLE MF, SCOTT DG: Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab. BMJ 2004; 329: 1266.
24. AMJADI S, MARANIAN P, FURST DE et al.: Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicentre, double-blind, randomized controlled trials. Arthritis Rheum 2009; 60: 2490-8.
25. DENTON CP, MERKEL PA, FURST DE et al.: Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007; 56: 323-33.
26. KALDAS M, KHANNA PP, FURST DE et al: Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis-assessment of individual body sites in two large randomized controlled trials. Rheumatology (Oxford). 2009; 48: 1143-6.
27. POSTLETHWAITE AE, WONG WK, CLEMENTS P et al.: A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. Arthritis Rheum 2008; 58: 1810-22.
28. WALKER UA, TYNDALL A, CZIRJAK L et al.: Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007; 66: 754-63.
29. LINSTONE H, TUROFF M (Eds.): The Delphi Method. Techniques and Applications: New Jersey Institute of Technology, California, USA; 2002.
30. JONES J, HUNTER D: Consensus methods for medical and health services research. BMJ 1995; 311: 376-80.
31. GENERINI S, STEINER G, MINIATI I et al.: Anti-hnRNP and other autoantibodies in systemic sclerosis with joint involvement. Rheumatology (Oxford). 2009; 48: 920-5.
32. MATUCCI-CERINIC M, ALLANORE Y, CZIRJAK L et al.: The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy. Ann Rheum Dis 2009; 68: 1377-80.